Sunday, June 2, 2024

6:30 PM – 7:30 PM CT

Please note this live virtual meeting is at: 7:30 PM Eastern; 6:30 PM Central; 5:30 PM Mountain; 4:30 PM Pacific

This enduring TeleECHO educational series is designed to assist members of the multi-disciplinary oncology care team in identifying approaches to the use of novel bispecific antibody therapies in later-line management of B-cell non-Hodgkin's lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and potential adverse events associated with bispecific antibody therapy, as well as discussion of best practices for multidisciplinary management of B-cell NHL to improve long-term clinical outcomes.

RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025

This educational enduring program will help healthcare professionals to optimize patient outcomes for those with advanced melanoma without actionable melanoma mutations. Specifically, the programming will improve clinicians’ knowledge of the latest data concerning appropriate assessment of melanoma from a clinical pathologic view and familiarize them with current updates with single-agent and combination therapy in advanced melanoma across settings of care, while preparing them to best manage adverse events across these therapies.

RELEASED DATE: June 30, 2023
EXPIRATION DATE: June 30, 2024

This enduring activity will explore the management of patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) through didactic slide review, case study discussion, and a robust Q&A session. This program will address the role of genetic and molecular markers in treatment selection as well as best practices for treatment of newly diagnosed, relapsed/refractory, and secondary AML. A summary of approaches to treatment-related adverse event recognition and mitigation will also be discussed.

RELEASED DATE: August 14, 2023
EXPIRATION DATE: August 14, 2024

This activity is designed to meet the educational needs of medical oncologists, oncology nurses, pharmacists, nurse practitioners, and other members of the multidisciplinary team to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC.

RELEASED DATE: August 15, 2023
EXPIRATION DATE: August 15, 2024

The Virtual Pathway activity will inform clinicians of the rationale for use of immunotherapy in cutaneous squamous cell carcinoma (cSCC), including the reasoning behind investigations of its use in the neoadjuvant or adjuvant settings. Through this interactive experience that incorporates didactic presentations, illustrative animations, and case-based discussion, clinicians will be exposed to current perspectives on the pathophysiology of early cSCC, how immunotherapy before and/or after surgery may improve outcomes, and available data from clinical study of neoadjuvant immunotherapy for cSCC.

RELEASED DATE: July 28, 2023
EXPIRATION DATE: July 28, 2024

This enduring educational program will help participants understand the role of HER3 biology to better manage patients with advanced non-small cell lung cancer (NSCLC), including EGFR tyrosine kinase inhibition (TKI)-resistant tumors; review HER3-targeted therapeutics available for patients with advanced NSCLC with EGFR-activating mutations; and highlight the value of multidisciplinary management of treatment-related adverse events. This enduring program combines didactic instruction with case-based discussions and animations.

RELEASED DATE: December 08, 2023
EXPIRATION DATE: December 08, 2024

This enduring activity takes learners on a compelling journey in managing chronic graft-versus-host disease (cGVHD) by explaining the evidence-based diagnostic criteria for cGVHD for prompt diagnosis; discussing the clinical safety and efficacy data of recently approved and investigational therapeutic agents, and finally, developing strategies to create treatment plans that address the psychosocial impact of disease and prioritize improvement in quality of life. Learners are invited to explore challenging aspects of this condition with the goal of informing selection of the most appropriate treatment regimens targeting disease etiopathogenesis. This immersive experience highlights the importance of early recognition in the effective management of cGVHD.

RELEASED DATE: June 16, 2023
EXPIRATION DATE: June 16, 2024

Friday, May 31, 2024

6:30 PM – 7:30 PM CT

Please note this live virtual meeting is at: 7:30 PM Eastern; 6:30 PM Central; 5:30 PM Mountain; 4:30 PM Pacific

This enduring educational activity focuses on the care of patients with advanced/metastatic gastric cancer and gastroesophageal junction adenocarcinoma. The program aims to help healthcare professionals improve their ability to evaluate which patient populations may benefit from anti-angiogenic therapy as a second-line treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers, and to select appropriate second- and subsequent-line therapy based on clinical practice guidelines and the latest clinical trial findings.

RELEASED DATE: October 13, 2023
EXPIRATION DATE: November 28, 2024